Research Triangle Park-based Tranzyme Pharma has given the generic name of "ulimorelin" to its experimental drug TZP-101 for treating gastroparesis, an inability of the stomach to empty food efficiently.
The federal agency established to approve drug naming okayed ulimorelin as the designation for the drug Tranzyme believes will treat the digestive problem, which is especially troublesome for diabetics.
The North Carolina Biotechnology Center helped in Tranzyme's early development with a $150,000 loan. Vipin Garg, Ph.D., Tranzyme's president and CEO, subsequently served on the Biotechnology Center's board of directors.
TZP-101 has shown positive results in clinical studies.